Department of Veterinary Medicine, University of Bari, Valenzano, Italy.
Boehringer Ingelheim Animal Health, Lyon, France.
Vet Parasitol. 2021 Dec;300:109607. doi: 10.1016/j.vetpar.2021.109607. Epub 2021 Oct 29.
Otodectes cynotis is a commonly occurring surface mite that can be easily transmitted between suitable hosts, including dogs, causing otocariosis. The activity of the systemic insecticide afoxolaner against O. cynotis has been tested once under experimental conditions, showing a high efficacy. The present study aimed to i) assess the efficacy of two consecutive monthly oral administrations of afoxolaner (NexGard®) against O. cynotis in naturally infested dogs under field conditions and ii) evaluate its impact in reducing bacteria or fungal secondary infections. Dogs, positive for O. cynotis (n = 20), were included in the study and allocated in two groups of ten animals each (G1, control group, and G2, treated group). The first group of ear mite-infested dogs was treated with a placebo, while afoxolaner was administered orally to the second group of dogs at Day 0 (D0) and Day 30 (D30), following label instructions. Otoscopic assessments, deep-swab method and swab samples were performed on all dogs (Days 0, 30, 42) to evaluate the presence or absence of live mites and their number throughout the study, as well as to conduct bacterial and fungal assessments. No adverse events likely related were recorded throughout the study. By Day 42 (D42), all dog's ears were flushed to recover ear mites. All treated dogs became negative, as well as two dogs of the control group. The treatment efficacy of afoxolaner was 100 % based on the arithmetic means of the live mite counts. The clinical scores did not change significantly in the control group, whereas they significantly improved in the treated one from D0 to D30 (p-value = 5.47 10). No live mites were present in the afoxolaner-treated group at D42 (p-value = 0.00073). In this field study, two oral administrations of afoxolaner at the recommended dose allowed a complete cure of the infestation. Bacterial and Malassezia pachydermatis infections were detected in both groups, although no significant trend was associated to the ear mite treatment.
耳痒螨是一种常见的体表螨,可在包括犬在内的合适宿主之间轻易传播,引起耳炎。曾在实验条件下对系统性杀虫剂氟虫腈(afoxolaner)杀灭耳痒螨的效果进行过一次测试,显示出很高的功效。本研究旨在:i)评估在野外条件下,对自然感染耳痒螨的犬连续两次每月口服氟虫腈(NexGard®)对耳痒螨的疗效;ii)评估其对减少细菌或真菌继发感染的影响。将 20 只耳痒螨阳性犬纳入本研究,并将其分为两组,每组 10 只动物(G1,对照组;G2,治疗组)。第一组感染耳痒螨的犬接受安慰剂治疗,而第二组犬则按照标签说明在第 0 天(D0)和第 30 天(D30)口服氟虫腈。在整个研究过程中,对所有犬(D0、D30、D42)进行耳镜检查、深拭子法和拭子样本检查,以评估活螨的存在和数量及其在整个研究过程中的数量,以及进行细菌和真菌评估。在整个研究过程中,未记录到任何可能与之相关的不良事件。到第 42 天(D42),所有犬的耳朵都被冲洗干净,以回收耳螨。所有接受治疗的犬均转为阴性,对照组中有 2 只犬也转为阴性。根据活螨计数的算术平均值,氟虫腈的治疗效果为 100%。对照组的临床评分无明显变化,而治疗组从 D0 到 D30 则显著改善(p 值=5.47 10)。在 D42 时,在接受氟虫腈治疗的组中未发现活螨(p 值=0.00073)。在这项现场研究中,按推荐剂量口服两次氟虫腈可完全治愈感染。在两组中均检测到细菌和马拉色菌感染,尽管与耳螨治疗无关,但未发现明显趋势。